Vitamin D As Predictor Of Multiple Sclerosis Activity And Progression In Patients With CIS Treated Early With Interferon beta-1b (P5.016)
Bibliographic record
Abstract
OBJECTIVE: To examine the predictive effects of 25(OH)D on disease activity and prognosis in patients starting IFNB-1b at the CIS and the effect of 25(OH)D on the occurrence of flu-like symptoms (FLS) during treatment. BACKGROUND: The BENEFIT study examined the effects of interferon beta-1b (IFNB-1b) in clinically isolated syndrome (CIS). In prior analyses 25-hydroxyvitamin D (25[OH]D) contributed to the prediction of rate of conversion to clinically definite multiple sclerosis (CDMS), MS activity, and rate of progression up to 5-years after CIS. DESIGN/METHODS: Patients with a first clinical demyelinating event and >=2 clinically silent brain MRI lesions randomized to early IFNB-1b treatment with serum 25(OH)D concentration measurements at baseline, 6, 12, and 24 months were included. Clinical and MRI follow-up lasted for 5 years. Cox proportional hazard models or generalized mixed effects models related season-adjusted 25(OH)D concentrations to outcomes. Occurrence of FLS was compared by Chi-Square. RESULTS: Patients were dichotomized into high (>=50 nmol/L) and low (<50 nmol/L) 25(OH)D groups based on season-adjusted 25(OH)D up to 12 months. From Year 1 to Year 5, patients with high 25(OH)D had a lower probability of conversion to CDMS (RR [95% CI]: 0.47 [0.28;0.80], score [logrank] test=8.14 on 1 df, p=0.0043, N=187), cumulative number of new lesions (RR [95% CI]: 0.70 [0.54;0.90], p=0.0055, N=216), percent change in T2 volume (high vs. low: -10 [-19;-2], p=0.016, N=213), and percent change in brain volume (high vs. low: 0.43 [0.14;0.72], p=0.0037, N=170). Occurrence of FLS did not differ between groups at Months 6, 12, and 24 (p>0.28). CONCLUSIONS: Among patients who started IFNB-1b treatment right after CIS, low 25(OH)D levels were a strong risk factor for long-term MS activity and severity but not for the occurrence of FLS, suggesting a role of vitamin D supplementation as an add-on to IFNB-1b in early treatment of patients with MS. Study Supported by: Bayer HealthCare Pharmaceuticals
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".